Compare Herbalife Nutrition Ltd (HLF) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Lam Research Corporation — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Lam Research Corporation trades at $318.84 (market cap $401.19B). The key difference: Lam Research Corporation is far larger — about 299.4× Herbalife Nutrition Ltd's market cap, and Lam Research Corporation pays a 0.41% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Lam Research Corporation for 60 Days on average.
| HLF | LRCX | |
|---|---|---|
Market Cap | $1.34B | $401.19B |
Volume | 1,589,457 | 8,960,892 |
Sector | Consumer Staples | Technology |
52-Week High | $19.96 | $433.33 |
52-Week Low | $7.75 | $131.37 |
Typical Hold Time | 43 Days | 60 Days |
Enterprise Value | $3.18B | $399.35B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.82, up 1.34% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue has been stable around $5.0B annually, with a net income margin of 4.53% in 2025. Recent news includes a $250 million share repurchase program and a planned CEO transition effective October 31, 2026.
The stock appears undervalued with a P/E of 8.22 and P/S of 0.26, supported by a 53.84% analyst buy rating and a $19.00 consensus price target. Key risks include high debt levels, with total liabilities at $3.53B, and inconsistent earnings performance. Positive cash flow trends in 2026 projections and margin expansion plans offer potential upside, but investor caution is warranted due to ongoing leadership changes and competitive pressures.
Lam Research (LRCX) trades at $320.59, down 2.71% on the day, amid a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.82 surpassing the $1.69 estimate, and maintains high profitability with a net income margin of 31.27%. Revenue growth is accelerating, reaching $18.44 billion in 2025, supported by AI-driven demand for semiconductor equipment. Analyst consensus remains strongly bullish with a $375.68 price target, though technical indicators show mixed signals with key support at $314.
LRCX presents a compelling long-term investment opportunity driven by AI infrastructure spending and operational efficiency, but faces near-term volatility from technical bearishness and macroeconomic headwinds. Risks include cyclical semiconductor demand and competitive pressures, yet strong institutional support and consistent earnings outperformance underpin upside potential toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
